AF-DX 250

{{Infobox drug | name = AF-DX 250 | image = | width = 250px | alt = | caption = Chemical structure of AF-DX 250 | IUPAC_name = 11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one | CAS_number = 104632-27-1 | PubChem = 6917844 | ChemSpiderID = 5293703 | UNII = 0F1Q1Z2P0T | KEGG = D02795 | ChEMBL = 2104010 | C=23 | H=30 | N=4 | O=2 | molecular_weight = 394.51 g/mol }}

AF-DX 250 is a selective muscarinic receptor antagonist, primarily targeting the M2 and M4 subtypes. It is a member of the benzodiazepine class of compounds, although it does not exhibit the typical anxiolytic or sedative properties associated with other benzodiazepines. Instead, AF-DX 250 is utilized in research settings to study the physiological and pharmacological roles of muscarinic receptors.

Pharmacology

AF-DX 250 exhibits a high affinity for the M2 and M4 muscarinic acetylcholine receptors, which are G protein-coupled receptors involved in various central and peripheral nervous system functions. The M2 receptors are predominantly found in the heart, where they play a crucial role in modulating cardiac function, while M4 receptors are primarily located in the central nervous system.

By selectively blocking these receptors, AF-DX 250 is used to investigate the specific roles of M2 and M4 receptors in physiological processes such as cardiac regulation, neurotransmitter release, and cognitive functions. This selectivity makes AF-DX 250 a valuable tool in both in vitro and in vivo studies.

Mechanism of Action

AF-DX 250 acts as a competitive antagonist at the M2 and M4 muscarinic receptors. By binding to these receptors, it prevents the endogenous ligand, acetylcholine, from exerting its effects. This blockade results in altered physiological responses, which can be studied to understand the underlying mechanisms of muscarinic receptor function.

Applications in Research

AF-DX 250 is primarily used in experimental research to:

• Study the role of M2 receptors in cardiac function and their potential as therapeutic targets in cardiovascular diseases.
• Investigate the involvement of M4 receptors in neurological processes and their implications in disorders such as schizophrenia and Parkinson's disease.
• Explore the pharmacological properties of muscarinic receptors and develop new drugs targeting these receptors.

Safety and Handling

As with many research chemicals, AF-DX 250 should be handled with care. Appropriate safety measures, including the use of personal protective equipment and proper laboratory protocols, should be followed to minimize exposure and potential risks.

Also see

• Muscarinic receptor
• Acetylcholine
• Benzodiazepine
• Cardiac function
• Neurotransmitter

Benzodiazipines

• Alprazolam
• Chlordiazepoxide
• Diazepam (Oral)
• Estazolam
• Flurazepam
• Lorazepam
• Midazolam
• Oxazepam
• Quazepam
• Temazepam
• Triazolam

Anticonvulsants Drugs

• Clobazam
• Clonazepam
• Clorazepate
• Diazepam (Intravenous)

Drug class for AF-DX 250

Anticonvulsants, and Benzodiazepines]